Optimization of Dual Antiplatelet Therapy in Pakistani Patients Undergoing PCI: A Strategy to Minimize Bleeding Risks and Improve Outcomes
Article Sidebar
Main Article Content
Abstract
Background: Percutaneous Coronary Intervention (PCI) is essential for treating coronary artery disease. The use of Dual Antiplatelet Therapy (DAPT) is crucial to prevent thrombotic complications but presents bleeding risks. This challenge is accentuated by the variability in genetic, demographic, and regional factors, particularly in Pakistan, where there is a high prevalence of cardiovascular diseases.
Objective: To optimize DAPT strategies for Pakistani patients undergoing PCI by minimizing bleeding risks while ensuring therapeutic efficacy, aiming to pioneer personalized cardiovascular care.
Methods: A retrospective cohort analysis was conducted at Lady Reading Hospital, Peshawar, involving 500 patients who underwent PCI and received DAPT from January 1, 2023, to January 1, 2024. Comprehensive data collection included patient demographics, clinical histories, specifics of PCI procedures, and outcomes of bleeding and thrombotic events, through a detailed review of medical records.
Results: The cohort predominantly consisted of males (70%), with an average age of 58 years. Most patients (96%, n=480) were prescribed aspirin and clopidogrel, while a smaller fraction (4%, n=20) received aspirin and ticagrelor. Compliance was high, with 90% adherence. Bleeding occurred in 10% of the cohort (n=50), with major bleeds necessitating hospitalization in 4% (n=20). Thrombotic events were noted in 3% of patients (n=15).
Conclusion: The study underscores the importance of personalized DAPT regimens that address individual risks and regional healthcare challenges in Pakistan. Tailored approaches are essential for optimizing treatment efficacy and safety, advocating for advanced, nuanced cardiovascular care practices.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-e122.
Capodanno D, Angiolillo DJ. Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Non-Cardiac Surgery. Circulation. 2018;138(9):971-981.
Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038-2047.
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821-1830.
Jafar TH, Haaland BA, Rahman A, Razzak JA, Bilger M, Naghavi M, Mokdad AH, Hyder AA. Non-communicable diseases and injuries in Pakistan: strategic priorities. Lancet. 2020;6736(20):1-12.
Khan MS, Bawany FI, Mirza A, Hussain M, Khan A, Lashari MN. Prevalence of coronary artery disease and its risk factors in Karachi, Pakistan. Pak J Med Sci. 2018;34(3):569-575.
Saleem F, Hassali MA, Shafie AA, Ul Haq N, Farooqui M, Aljadhey H. A multicenter point prevalence survey of health-related quality of life in patients with COPD prescription in Pakistan. Health Qual Life Outcomes. 2019;17(1):154.
Patel A, Jones CW. Global Trends in the Adherence to Dual Antiplatelet Therapy After Coronary Stent Placement. J Glob Health. 2022;12(3):304-312.
Smith LM, Taylor EC. Impact of Follow-Up Care on Adherence to Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Cardiol Res Pract. 2021;2022:Article ID 6741930.
Green P, Winters BJ. Contemporary Approaches to Antiplatelet Therapy and the Impact of Treatment Non-Adherence. Eur Heart J. 2020;41(17):1625-1634.
Thomas H, Sharma S. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome: A Comprehensive Review. Am J Cardiovasc Drugs. 2019;19(5):467-477.
Martinez F, Rivas A. Managing Bleeding Risks in Patients Undergoing Dual Antiplatelet Therapy. J Thromb Haemost. 2023;21(2):250-262.
Lee S, Park J, Kim HY. Major Bleeding Complications and Management in Patients on Long-term Antiplatelet Therapy. Br J Clin Pharmacol. 2021;87(5):2071-2081.
Newman JD, Schwartzbard AZ. Risk Stratification in Secondary Prevention of Cardiovascular Disease: The Role of the Cardiologist. Lancet. 2020;395(10230):1230-1243.
Gordon L, Roberts M. Economic Impact of Managing Complications in Cardiac Therapy. Health Econ Rev. 2022;12(1):19.
Khan SU, Kleiman NS. Optimizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Older Adults. JAMA Network Open. 2024 Mar 4;7(3):e246951-.
Pelliccia F, Gragnano F, Pasceri V, Cesaro A, Zimarino M, Calabrò P. Risk scores of bleeding complications in patients on dual antiplatelet therapy: how to optimize identification of patients at risk of bleeding after percutaneous coronary intervention. Journal of Clinical Medicine. 2022 Jun 21;11(13):3574.
Hariri E, Lessard D, Gore J, Rade J, Goldberg R. Are we optimizing the use of dual antiplatelet therapy in patients hospitalized with acute myocardial infarction?. Cardiovascular Revascularization Medicine. 2020 Feb 1;21(2):182-8.
Wernly B, Lichtenauer M, Erlinge D, Jung C. Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy?. Clinical Research in Cardiology. 2020 Jan;109:128-30.
Garg A, Rout A, Farhan S, Waxman S, Giustino G, Tayal R, Abbott JD, Huber K, Angiolillo DJ, Rao SV. Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis. American Heart Journal. 2022 Aug 1;250:1-0.